featured
Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer (COSMIC-311)
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer (COSMIC-311): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet Oncol 2021 Jul 05;[EPub Ahead of Print], MS Brose, B Robinson, SI Sherman, J Krajewska, CC Lin, F Vaisman, AO Hoff, E Hitre, DW Bowles, J Hernando, L Faoro, K Banerjee, JW Oliver, B Keam, J CapdevilaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.